SynthesisRadiology. Imaging cancer2022
Open access · diamondAbstract readMeta-AnalysisSystematic Review
In one paragraph
Synthesis in Radiology. Imaging cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era.La Radiologia medica · 2026Review
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- Differences in residual lesion detection after treatment of metastatic prostate cancer based on dual-tracer PET/CT.Frontiers in oncology · 2026Article
- Application value of radiomics features based on PSMA PET/CT in diagnosis of clinically significant prostate cancer: a comparison between manual and automatic segmentation.BMC medical imaging · 2025Article
- Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.European journal of nuclear medicine and molecular imaging · 2024Review
- Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.Current treatment options in oncology · 2024Review
- Prostate Cancer-PET Imaging Update.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Divya YadavFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).ORCID 0000-0003-3370-7662
Hyunsoo HwangFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).
Wei QiaoFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).ORCID 0000-0002-0922-0726
Rituraj UpadhyayFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).
Brian F ChapinFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).ORCID 0000-0003-3225-9976
Chad TangFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).
Ana AparicioFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).ORCID 0000-0003-0900-0923
Maria A Lopez-OlivoFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).
Stella K KangFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).
Homer A MacapinlacFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).
Tharakeswara K BathalaFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).ORCID 0000-0001-8342-4519
Devaki Shilpa SurasiFrom the Departments of Radiation Oncology (D.Y., R.U., C.T.), Biostatistics (H.H., W.Q.), Urology (B.F.C.), Genitourinary Medical Oncology (A.A.), Health Services Research (M.A.L.O.), Nuclear Medicine (H.A.M., D.S.S.), and Abdominal Imaging (T.K.B.), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 483, Houston, TX 77030; and Department of Radiology, NYU Langone Health, New York, NY (S.K.K.).ORCID 0000-0003-3174-1138
The University of Texas MD Anderson Cancer Center · US
Funding
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibitionK08CA237619 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOPEZ-OLIVO, MARIA DE LOS ANGELES · 2020 to 2024
$938kNCI NIH HHS K08 CA237619
Abstract
Purpose Fluorine 18 (
Indexed as
Positron Emission Tomography Computed TomographyProstatic NeoplasmsHumansMalePositron-Emission TomographyProstateRadiopharmaceuticalsRadiopharmaceuticalsMolecular Imaging–CancerPETProstateStaging
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.